TY  - JOUR
T1  - The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: A randomized, placebo-controlled, clinical trial
AU  - Kelly AS, Rudser KD, Nathan BM, et al
Y1  - 2013/04/01
N1  - 10.1001/jamapediatrics.2013.1045
JO  - JAMA Pediatrics
SP  - 355
EP  - 360
VL  - 167
IS  - 4
N2  - Importance 
                  Medical treatment options for pediatric obesity remain limited. Glucagon-like peptide-1 (GLP-1) receptor agonists induce weight loss by suppressing appetite and increasing satiety, but few studies have evaluated this therapy as a treatment for obesity.Objective 
                  To evaluate the effects of exenatide on body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and cardiometabolic risk factors in adolescents with severe obesity.Design 
                  Three-month, randomized, double-blind, placebo-controlled, multicenter clinical trial followed by a 3-month open-label extension.Setting 
                  An academic medical center and an outpatient pediatric endocrinology clinic.Patients 
                  A total of 26 adolescents (12-19 years of age) with severe obesity (BMI ≥ 1.2 times the 95th percentile or BMI ≥ 35).Intervention 
                  All patients received lifestyle modification counseling and were equally randomized to exenatide or placebo injection, twice per day.Main Outcome Measures 
                  The primary end point was the mean percent change in BMI measured at baseline and 3 months. Secondary end points included absolute change in BMI, body weight, body fat, blood pressure, hemoglobin A1c, fasting glucose, fasting insulin, and lipids at 3 months.Results 
                  Twenty-two patients completed the trial. Exenatide elicited a greater reduction in percent change in BMI compared with placebo (−2.70% [95% CI, −5.02% to −0.37%]; P = .03). Similar findings were observed for absolute change in BMI (−1.13 [95% CI, −2.03 to −0.24]; P = .02) and body weight (−3.26 kg [95% CI, −5.87 to −0.66 kg]; P = .02). Although not reaching the level of statistical significance, reduction in systolic blood pressure was observed with exenatide. During the open-label extension, BMI was further reduced in those initially randomized to exenatide (cumulative BMI reduction of 4%).Conclusions and Relevance 
                  These results provide preliminary evidence supporting the feasibility, safety, and efficacy of GLP-1 receptor agonist therapy for the treatment of severe obesity in adolescents.Trial Registration 
                  clinicaltrials.gov Identifier: NCT01237197
SN  - 2168-6203
M3  - doi: 10.1001/jamapediatrics.2013.1045
UR  - http://dx.doi.org/10.1001/jamapediatrics.2013.1045
ER  -